ProShare Advisors
MRSN

ProShare Advisors’s Mersana Therapeutics MRSN Stock Holding History

ProShare Advisors’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,151
Closed -$9.91K – 2145
2025
Q1 		$9.91K Sell
1,151
-361
-24% -$5.57K ﹤0.01% 2068
2024
Q4 		$54.1K Buy
1,512
+655
+76% +$33.9K ﹤0.01% 2168
2024
Q3 		$40.5K Buy
857
+263
+44% +$11.6K ﹤0.01% 2000
2024
Q2 		$29.8K Sell
594
-203
-25% -$14.7K ﹤0.01% 1786
2024
Q1 		$89.2K Buy
797
+63
+9% +$6.26K ﹤0.01% 1839
2023
Q4 		$42.6K Sell
734
-128
-15% -$5.15K ﹤0.01% 1878
2023
Q3 		$27.4K Buy
862
+44
+5% +$2.09K ﹤0.01% 1766
2023
Q2 		$67.3K Buy
818
+83
+11% +$12.1K ﹤0.01% 1744
2023
Q1 		$75.5K Sell
735
-71
-9% -$9.96K ﹤0.01% 1631
2022
Q4 		$118K Buy
806
+82
+11% +$13.9K ﹤0.01% 1618
2022
Q3 		$122K Buy
724
+28
+4% +$4.55K ﹤0.01% 1514
2022
Q2 		$80K Sell
696
-186
-21% -$17.5K ﹤0.01% 1645
2022
Q1 		$88K Sell
882
-149
-14% -$17.4K ﹤0.01% 2056
2021
Q4 		$161K Buy
1,031
+51
+5% +$9.92K ﹤0.01% 2107
2021
Q3 		$231K Sell
980
-235
-19% -$68.7K ﹤0.01% 1714
2021
Q2 		$412K Buy
1,215
+264
+28% +$99.9K ﹤0.01% 1676
2021
Q1 		$385K Buy
951
+56
+6% +$27.2K ﹤0.01% 1633
2020
Q4 		$595K Buy
+895
New +$498K ﹤0.01% 1153
2018
Q4 		– Sell
-439
Closed -$110K – 1654
2018
Q3 		$110K Sell
439
-12
-3% -$4.02K ﹤0.01% 1671
2018
Q2 		$201K Sell
451
-27
-6% -$11.9K ﹤0.01% 1606
2018
Q1 		$188K Sell
478
-42
-8% -$16.6K ﹤0.01% 1563
2017
Q4 		$214K Buy
+520
New +$227K ﹤0.01% 1605

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

ProShare Advisors's MRSN Position: Q2 2025 in Review

ProShare Advisors sold out of Mersana Therapeutics (MRSN) in Q2 2025, closing a stake of 1,151 shares — an estimated $9.91K sold.

ProShare Advisors first reported a position in MRSN in Q4 2017 and held it in 22 quarters. The position peaked at $595K in Q4 2020. 83 funds tracked by Wall St. Rank hold MRSN as of Q2 2025.

  • ProShare Advisors reported no remaining Mersana Therapeutics position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 1,151 Mersana Therapeutics shares in Q2 2025, an estimated $9.91K.
  • ProShare Advisors first reported a position in Mersana Therapeutics in Q4 2017 and held it in 22 quarters.
  • ProShare Advisors's Mersana Therapeutics position peaked at $595K in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.